Methods to analyze chemopreventive effect of silibinin on prostate cancer biomarkers protein expression

Methods in Pharmacology and Toxicology

Volumn , Issue , 2014, Pages 85-105

  Deep, Gagan ^a,b   Inturi, Swetha ^a,b   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Biomarkers; Chemoprevention; Confocal; Immunoblotting; Immunofluorescence; Immunohistochemistry; Prostate cancer; Silibinin

Indexed keywords

BIOLOGICAL MARKER; SILIBININ; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CANCER SCREENING; CELL ASSAY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SILYBUM MARIANUM;

EID: 84891757674     PISSN: 15572153     EISSN: 19406053     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9227-6_4     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
2. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609-2617
3. Tantivejkul K, Kalikin LM, Pienta KJ (2004) Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91(4):706-717
4. Hadaschik BA, Gleave ME (2007) Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25(5):413-419
5. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP (1998) Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152(1):1-9
6. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1):34-45
7. Harzstark AL, Ryan CJ (2008) Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs 17(1):13-22
8. Petrylak DP (2005) The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65(Suppl 5):3-7, Discussion 7-8
9. Deep G, Agarwal R (2007) Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 6(2):130-145. doi: 10.1177/ 1534735407301441
10. Wattenberg LW (1997) An overview of chemoprevention: current status and future prospects. Proc Soc Exp Biol Med 216(2):133-141
11. Agarwal R (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60(8):1051-1059
12. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3(10):768-780
13. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R (2008) Stagespecific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 68(16):6822-6830. doi: 10.1158/0008-5472. CAN-08-1332
14. Deep G, Agarwal R (2010) Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 29(3):447-463. doi: 10.1007/s10555-010-9237-0
15. Singh RP, Agarwal R (2006) Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 13(3):751-778
16. Kavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal R (2012) Silibinin inhibits prostate cancer cells-and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-kappaB, and AP-1 Activation in RAW264.7 cells. Mol Carcinog. doi: 10.1002/mc.21959
17. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26(6B):4457-4498
18. Pradhan SC, Girish C (2006) Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124(5):491-504
19. Deep G, Gangar SC, Agarwal C, Agarwal R (2011) Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 4(8):1222-1232. doi: 1940-6207.CAPR-10-0370.10.1158/ 1940-6207.CAPR-10-0370
20. Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M (2010) A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. J Prostate 70(8):848-855. doi: 10.1002/pros.21118
21. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM (2007) A phase I and pharmaco-kinetic study of silybin-phytosome in prostate cancer patients. Investig New Drugs 25(2): 139-146
22. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ (2006) Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 12(9):2944-2950
23. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R (2006) Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Canc Inst 98(12):846-855
24. Roy S, Gu M, Ramasamy K, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R (2009) p21/Cip1 and p27/Kip1 are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res 69(3):1166-1173. doi: 10.1158/0008-5472.CAN-08-3115
25. Tyagi A, Sharma Y, Agarwal C, Agarwal R (2008) Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res, 25:2143-2150
26. Zi X, Grasso AW, Kung HJ, Agarwal R (1998) A fl avonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 58(9): 1920-1929
27. Singh RP, Agarwal R (2006) Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45(6):436-442
28. Deep G, Gangar SC, Rajamanickam S, Raina K, Gu M, Agarwal C, Oberlies NH, Agarwal R (2012) Angiopreventive efficacy of pure fl avonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. PloS One 7(4):e34630. doi: 10.1371/journal.pone.0034630
29. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24(7):1188-1202
30. Deep G, Agarwal R (2013) Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Target 13:486-499
31. Singh RP, Raina K, Sharma G, Agarwal R (2008) Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 14(23):7773-7780. doi: 10.1158/1078-0432.CCR-08-1309
32. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of fl avanone silibinin with fl avanolignan mixture silymarin. Oncogene 25(7):1053-1069
33. Zi X, Agarwal R (1999) Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 96(13):7490-7495
34. Singh RP, Raina K, Deep G, Chan D, Agarwal R (2009) Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 15(2):613-621. doi: 10.1158/1078-0432.CCR-08-1846
35. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R (2007) Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28(12): 2567-2574. doi: 10.1093/carcin/bgm218
36. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R (2002) Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 62(11):3063-3069
37. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glode LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R (2007) Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67(22): 11083-11091
38. Zhu W, Zhang JS, Young CY (2001) Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22(9):1399-1403
39. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH (2004) Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 171(5):1934-1938
40. Hansen J, Rink M, Graefen M, Shariat S, Chun FK (2013) Assays for prostate cancer: changing the screening paradigm? Mol Diagn Ther 17(1):1-8. doi: 10.1007/s40291-013-0014-y
41. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R (2003) Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 12(9): 933-939
42. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, Agarwal R (2008) Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: comparison with silymarin and silibinin. Int J Cancer 123(12):2750-2758. doi: 10.1002/ijc.23879
43. Zi X, Zhang J, Agarwal R, Pollak M (2000) Silibinin up-regulates insulin-like growth factorbinding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60(20):5617-5620